Search Results
Jul 02, 2026, 14:32 ET NNS erwirbt Anteile an OCI
im Zusammenhang mit dem Erhalt behördlicher Genehmigungen ohne unerwartete Verzögerungen oder Auflagen sowie die Möglichkeit behördlicher Maßnahmen; (iii) Risiken im Zusammenhang mit erheblichen Kosten der Transaktion; (iv) die erwartete finanzielle und operative Entwicklung sowie zukünftige Chancen nach
More news about: NNS Holding (Cyprus) Limited
Jul 02, 2026, 14:29 ET NNS adquiere acciones en OCI
riesgos relacionados con la obtención de aprobaciones regulatorias sin demoras o condiciones inesperadas y la posibilidad de acciones regulatorias; (iii) riesgos relacionados con costes significativos relacionados con la transacción; (iv) el rendimiento financiero y operativo esperado y las oportunidades
More news about: NNS Holding (Cyprus) Limited
Jul 02, 2026, 14:17 ET Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
(GBM). GBM is the most aggressive and lethal form of primary brain cancer, and is an "orphan disease." The Company has completed a 331-patient Phase III trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval
More news about: Northwest Biotherapeutics, Inc.
Jul 02, 2026, 13:13 ET NNS acquires shares in OCI
at all; (ii) risks relating to the receipt of regulatory approvals without unexpected delays or conditions and the possibility of regulatory action; (iii) risks relating to significant costs related to the transaction; (iv) the expected financial and operating performance and future opportunities following
More news about: NNS Holding (Cyprus) Limited
Jul 02, 2026, 13:10 ET NNS acquires shares in OCI
at all; (ii) risks relating to the receipt of regulatory approvals without unexpected delays or conditions and the possibility of regulatory action; (iii) risks relating to significant costs related to the transaction; (iv) the expected financial and operating performance and future opportunities following
More news about: NNS Holding (Cyprus) Limited
Jul 02, 2026, 10:31 ET Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
therapeutic options for these patient populations.Despite remarkable progress in precision oncology and immunotherapy, early-stage NSCLC (Stages I–III) continues to represent a significant area of unmet need. Surgical resection followed by adjuvant platinum-based chemotherapy remains the standard of
More news about: DelveInsight Business Research, LLP
Jul 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines - GRAL
information about joining the class action] On February 19, 2026, Grail announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail attributed this shortcoming, in part, to "probably need[ing] a longer follow-up time
More news about: Pomerantz LLP
Jul 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
action] On March 13, 2026, Immutep issued a press release "announc[ing] that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial
More news about: Pomerantz LLP
Jul 02, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against First Solar, Inc. and Certain Officers - FSLR
and attempted relocation of production to the U.S., were likely to negatively impact First Solar's projected performance in the 2026 fiscal year; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.The truth began to emerge on January 7,
More news about: Pomerantz LLP
Jul 02, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Nano-X Imaging Ltd. and Certain Officers - NNOX
demand for its products; (ii) in reality, Nano-X's production and manufacturing operations were poorly aligned with demand for the Company's products; (iii) as a result, Nano-X was experiencing significantly increased operating expenses and cash burn; (iv) the foregoing significantly increased the likelihood
More news about: Pomerantz LLP
Jul 02, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against BitGo Holdings, Inc. and Certain Officers - BTGO
Defendants' statements regarding, inter alia, BitGo's financial performance and business prospects as a public company lacked a reasonable basis; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and/or failed
More news about: Pomerantz LLP
Jul 02, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Lucid Group, Inc . and Certain Officers - LCID
deliveries of the Lucid Gravity; (ii) the foregoing was likely to, and did, have a material negative impact on the Company's business and financial results; (iii) accordingly, the Defendants had overstated the purported enhancements to Lucid's manufacturing and delivery capabilities and overall operations; and
More news about: Pomerantz LLP
Jul 02, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against AeroVironment, Inc. and Certain Officers - AVAV
U.S. Space Force's ongoing efforts to modernize the SCN; (ii) accordingly, Defendants overstated AeroVironment's business and financial prospects; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.On January 20, 2026, AeroVironment announced
More news about: Pomerantz LLP
Jul 02, 2026, 10:00 ET Avanos Medical, Inc. and American Industrial Partners Receive Required Regulatory Approvals for Pending Merger
Such factors include: (i) uncertainties as to the timing of the acquisition, (ii) the possibility that competing acquisition proposals will be made; (iii) the possibility that Avanos will terminate the merger agreement to enter into an alternative transaction; (iv) the possibility that various closing
More news about: Avanos Medical
Jul 02, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Graphic Packaging Holding Company and Certain Former Officers - GPK
and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company's business and financial results; (iii) Defendants likewise overstated the strength and sustainability of the Company's business model and operations, as well as its ability to weather ongoing
More news about: Pomerantz LLP
Jul 02, 2026, 09:28 ET GRAL SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
that the probability of achieving the statistical reduction in Stage III & IV cancers by the trial's end had been reduced.On February 19, 2026, Grail announced that the "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. The Company
More news about: Faruqi & Faruqi, LLP
Jul 02, 2026, 09:15 ET Hagerty Agrees to Acquire Bennetts to Become #2 Specialty Motorcycle Insurance Broker in the United Kingdom
(i) that the acquisition may not be completed on the expected terms or timeline, or at all; (ii) that the closing conditions may not be satisfied; (iii) that the anticipated benefits of the acquisition may not be realized, including earnings enhancements and synergies; (iv) that Hagerty may be unable
More news about: Hagerty
Jul 02, 2026, 09:00 ET Adventist HealthCare Shady Grove Medical Center Named Among Newsweek's Best U.S. Maternity Hospitals for 2026
a Level III neonatal intensive care unit, childbirth and parenting education classes, and comprehensive lactation support. Next door to the hospital, Shady Grove's
More news about: Adventist HealthCare Shady Grove Medical Center
Jul 02, 2026, 08:30 ET American Public University and American Military University Honor Student Achievement with Second Quarter 2026 President's List
Robert Steiskal IIIAndrew Fischer
More news about: American Public University System
Jul 02, 2026, 08:00 ET SK bioscience Launches AI-Powered Initiative to Reduce Uncertainty in Vaccine-Development Decisions
development, decisions on whether to advance into large-scale Phase III clinical trials are typically made based on Phase II trial results. However, in many vaccine fields, including rotavirus, decisions about whether to advance to large-scale Phase III trials are particularly challenging because validated immune
More news about: SK bioscience
Jul 02, 2026, 06:00 ET Hyperscale Data Buys 67 Bitcoin Bringing Bitcoin Treasury to Approximately 849 Bitcoin
believe in Bitcoin as a foundational asset of the future digital economy and of the Company's balance sheet," stated Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "We believe that Bitcoin will anchor our balance sheet and provide significant long-term value to
More news about: Hyperscale Data Inc.
Jul 02, 2026, 05:32 ET HiBy Products Receive Multiple Honors at VGP 2026 SUMMER
II — AwardedHiBy R8 II — AwardedHiBy Golden 10th Titanium Edition — AwardedHiBy R6 Pro II 2025 — AwardedHiBy R6 III 2025 — AwardedHiBy R3 Pro II — AwardedHiBy Digital M300 — AwardedHiBy ZETA II — AwardedHiBy Digital YUME — AwardedHiBy
More news about: HiBy
Jul 02, 2026, 05:14 ET NNS confirma el apoyo continuo a Rembrandt II
riesgos relacionados con la obtención de aprobaciones regulatorias sin demoras o condiciones inesperadas y la posibilidad de acciones regulatorias; (iii) riesgos relacionados con costes significativos relacionados con la transacción; (iv) el rendimiento financiero y operativo esperado y las oportunidades
More news about: NNS Holding (Cyprus) Limited
Jul 02, 2026, 05:09 ET HiBy Products Receive Multiple Honors at VGP 2026 SUMMER
II — AwardedHiBy R8 II — AwardedHiBy Golden 10th Titanium Edition — AwardedHiBy R6 Pro II 2025 — AwardedHiBy R6 III 2025 — AwardedHiBy R3 Pro II — AwardedHiBy Digital M300 — AwardedHiBy ZETA II — AwardedHiBy Digital YUME — AwardedHiBy
More news about: HiBy
Jul 02, 2026, 03:05 ET NNS confirme son soutien continu au projet Rembrandt II
risques liés à l'obtention des autorisations réglementaires sans retards ni conditions imprévus, ainsi que la possibilité de mesures réglementaires ; (iii) les risques liés aux coûts importants associés à l'opération ; (iv) les performances financières et opérationnelles attendues ainsi que les opportunités
More news about: NNS Holding (Cyprus) Limited